论文部分内容阅读
一些非随机研究结果提示,逐步增加缓解后的化疗强度可使存活率和CR期有不同程度的改善。东部肿瘤协作组(ECOG)对≤65岁的急性髓细胞白血病(AML)患者进行了随机研究,验证是否增加缓解后的化疗强度可改善患者的结局。病人和方法研究对象应符合下列条件:成人患者,年龄15～65岁,形态学属FAB分类M_1～M_7亚型,先前未曾化疗或放疗过,骨髓原始细胞>30%,既往无血液病,无明显心脏病,肝、肾功能正常。诱导缓解方案由柔红霉素、阿糖胞苷和硫鸟嘌呤组成,每个病人用1或2个
Some non-randomized studies suggest that gradually increasing the intensity of chemotherapy after remission may lead to some degree of improvement in survival and CR. The Eastern Cooperative Oncology Group (ECOG) conducted a randomized study of patients with Acute Myeloid Leukemia (AML) ≤65 years of age to demonstrate that increasing the intensity of chemotherapy after remission may improve the patient’s outcome. Patients and methods Subjects should meet the following criteria: Adult patients, aged 15 to 65 years, morphological FAB classification M_1 ~ M_7 subtype, previously chemotherapy or radiotherapy, bone marrow blast cells> 30%, no previous blood disease, no Obvious heart disease, liver and kidney function is normal. Induced remission program consists of daunorubicin, cytarabine and thioguanine, each patient with 1 or 2